IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma

IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma

Glioma is characterized by strong immunosuppression and excessive angiogenesis. Based on existing reports, it can be speculated that the resistance to anti-angiogenic drug vascular endothelial growth factor A (VEGFA) antibody correlates to the induction of novel immune checkpoint indoleamine 2,3-dio...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser: Zikang Xing, Xuewen Li, Zhen Ning Tony He, Xin Fang, Heng Liang, Chunxiang Kuang, Aiying Li, Qing Yang
Format: Artikel
Sprache:English
Veröffentlicht: MDPI AG 2024-06-01
Schriftenreihe:Pharmaceutics
Schlagworte:
glioma
angiogenesis
indoleamine 2,3-dioxygenase 1
tryptophan depletion
general control nonderepressible 2
Online Zugang:https://www.mdpi.com/1999-4923/16/7/870

Online

https://www.mdpi.com/1999-4923/16/7/870

Ähnliche Einträge